Dogwood Therapeutics raises $12.5M upfront; potential $14.4M from warrant exercise

Dogwood Therapeutics, Inc.

Gross proceeds of $12.5M from registered direct offering and concurrent private placement; potential additional $14.4M upon warrant exercise.
Offering priced at-the-market under Nasdaq rules: $2.85 per unit (share or pre-funded warrant plus Common Stock warrant).
Warrants exercisable at $3.28 per share, subject to stockholder approval, expire 5.5 years after approval.
Company terminated Northland at-the-market agreement; only $89,792 raised under that facility.
Proceeds to advance Halneuron Phase 2b final data readout and pursue strategic opportunities.

item 1.01 item 1.02 item 3.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Dogwood Therapeutics, Inc. entered into Registration Rights Agreement with the Investor (effective 2026-01-11).

Action: entry
Counterparty: the Investor
Effective: 2026-01-11

Exact text from the filing

On January 11, 2026, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Investor

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Dogwood Therapeutics, Inc. entered into Purchase Agreement with a single institutional investor valued at approximately $12.5 million (effective 2026-01-11).

Action: entry
Agreement: equity purchase
Counterparty: a single institutional investor
Value: approximately $12.5 million
Effective: 2026-01-11

Exact text from the filing

On January 11, 2026, Dogwood Therapeutics, Inc., a Delaware corporation (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with a single institutional investor named therein (the “Investor”) pursuant to which the Company agreed to sell and issue in a registered direct offering (the “Registered Offering”) to the Investor 2,338,948 shares of common stock

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Dogwood Therapeutics, Inc. terminated Equity Distribution Agreement (effective 2026-01-09).

Action: termination
Agreement: atm program
Effective: 2026-01-09

Exact text from the filing

On January 9, 2026, Dogwood Therapeutics, Inc., a Delaware corporation (the “Company”) provided notice of its termination, effective January 9, 2026, of the Equity Distribution Agreement, dated November 28, 2025 (the “Northland Agreement")

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Dogwood Therapeutics, Inc. entered into Placement Agency Agreement with Maxim Group LLC valued at approximately $12.5 million (effective 2026-01-11).

Action: entry
Agreement: underwriting
Counterparty: Maxim Group LLC
Value: approximately $12.5 million
Effective: 2026-01-11

Exact text from the filing

On January 11, 2026, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Maxim Group LLC (the “Placement Agent”)

View on SEC.gov

294 material agreements filed in the last 30 days. Browse all material agreements →

Dogwood Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-003211

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.